Background
dBET57 is a hybrid compound that drives the selective proteasomal degradation of bromodomain-containing protein 4 (BRD4).1 It is characterized as a proteolysis-targeting chimera (PROTAC) and contains JQ1, which binds bromo- and extra-terminal domain (BET) proteins, linked to thalidomide, a ligand for the E3 ubiquitin ligase cereblon. dBET57 is selective for inhibiting the interaction between cereblon and bromodomain 1 of BRD4 (BRD4BD1) over the interaction between cereblon and BRD4BD2 with apparent cooperativity factor α (αapp) values of 0.8 and less than 0.1, respectively, in an assay using purified bromodomains. It reduces BRD4BD1 protein levels in vitro with a half-maximal degradation (DC50) value of approximately 500 nM after five hours but does not reduce levels of BRD4BD2.
1.Nowak, R.P., DeAngelo, S.L., Buckley, D., et al.Plasticity in binding confers selectivity in ligand-induced protein degradationNat. Chem. Biol.14(7)706-714(2018)
没有评价数据